Patent · US Active

Pre-frontal cortex processing disorder speech, gait and limb impairments treatment

US10085414B2 · kind B2 · utility

2Cited by

7References

13Claims

0Family size

Assignee

GILROSE PHARMACEUTICALS, LLC · US

Inventors

Bruce Roseman · White Plains, US
Gilla Kaplan · New York, US

Key dates

Filing date	May 16, 2017
Grant date	Oct 2, 2018
Priority date	—
Expiry date	May 16, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.